New advances in targeted therapies for squamous cell carcinoma of the head and neck
- PMID: 21048493
- DOI: 10.1097/CAD.0b013e328341071e
New advances in targeted therapies for squamous cell carcinoma of the head and neck
Abstract
Several molecular pathways are deregulated and activated in squamous cell carcinoma of the head and neck making this disease attractive for targeted molecular therapies. Cetuximab, a monoclonal antibody that binds to the epidermal growth factor receptor, improves the overall survival when combined with radiation therapy or chemotherapy. Novels agents targeting different molecular pathways in squamous cell carcinoma of the head and neck are currently under development. Among them, dual (epidermal growth factor receptor/human epidermal growth factor receptor-2) or pan-human epidermal growth factor receptor inhibitors and drugs that target the insulin growth factor-1 receptor, the MET receptor, or the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway have shown either interesting preclinical activity or promising preliminary clinical efficacy. Angiogenesis inhibitors should be used with caution in squamous cell carcinoma of the head and neck due to the risk of tumor bleeding. However, only a minority of patients seems to benefit from these new approaches. Understanding the primary and acquired resistance mechanisms to predict the treatment efficacy is of crucial importance to allow a better patient selection.
Similar articles
-
Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.Curr Opin Oncol. 2008 May;20(3):256-63. doi: 10.1097/CCO.0b013e3282f9b575. Curr Opin Oncol. 2008. PMID: 18391623 Review.
-
Molecular-targeted therapies in head and neck cancer.Semin Radiat Oncol. 2012 Jul;22(3):207-13. doi: 10.1016/j.semradonc.2012.03.005. Semin Radiat Oncol. 2012. PMID: 22687945
-
Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy.Curr Opin Oncol. 2011 May;23(3):241-8. doi: 10.1097/CCO.0b013e328344f581. Curr Opin Oncol. 2011. PMID: 21358328 Review.
-
Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.Clin Adv Hematol Oncol. 2006 Aug;4(8):611-9. Clin Adv Hematol Oncol. 2006. PMID: 17099619 Review.
-
Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.Curr Opin Oncol. 2006 May;18(3):247-52. doi: 10.1097/01.cco.0000219253.53091.fb. Curr Opin Oncol. 2006. PMID: 16552236 Review.
Cited by
-
Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review.Curr Genomics. 2017 Feb;18(1):60-74. doi: 10.2174/1389202917666160803160934. Curr Genomics. 2017. PMID: 28503090 Free PMC article. Review.
-
mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer.ISRN Otolaryngol. 2012 Oct 18;2012:953089. doi: 10.5402/2012/953089. Print 2012. ISRN Otolaryngol. 2012. PMID: 23762622 Free PMC article.
-
Recurrent oral cancer: current and emerging therapeutic approaches.Front Pharmacol. 2012 Jul 30;3:149. doi: 10.3389/fphar.2012.00149. eCollection 2012. Front Pharmacol. 2012. PMID: 23060791 Free PMC article.
-
Antitumor Activity of Nanoparticles Loaded with PHT-427, a Novel AKT/PDK1 Inhibitor, for the Treatment of Head and Neck Squamous Cell Carcinoma.Pharmaceutics. 2021 Aug 12;13(8):1242. doi: 10.3390/pharmaceutics13081242. Pharmaceutics. 2021. PMID: 34452203 Free PMC article.
-
Adenosine induces intrinsic apoptosis via the PI3K/Akt/mTOR signaling pathway in human pharyngeal squamous carcinoma FaDu cells.Oncol Lett. 2018 May;15(5):6489-6496. doi: 10.3892/ol.2018.8089. Epub 2018 Feb 20. Oncol Lett. 2018. PMID: 29616118 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
